© пресс-служба инновационных организаций Томской области
TOMSK, Jul 3 – RIA Tomsk. Scientists of the Tomsk Cancer Research Institute developed unique radiopharmaceuticals for the diagnosis of malignant neoplasms; according to some parameters, their efficiency is five times higher than foreign analogues, the representative of the press service of the Tomsk National Research Medical Center (TNRMC) told RIA Tomsk on Wednesday.
The agency interlocutor noted that the Tomsk Cancer Research Institute, together with scientists from Tomsk Polytechnic University (TPU), is involved in the development of new, effective and affordable radiopharmaceuticals for the diagnosis of various oncological diseases.
According to her, the scientists developed original radiopharmaceutical based on aluminum gamma oxide marked with technetium-99m (99m Tc-Alotech) with the accumulation mechanism in sentinel nodes (the first barrier on the way of tumor cells. – Ed.) to personify the volume of surgical interventions in malignant tumors .
"It is shown that 99m Tc-Alotech is five times more efficiently accumulated in sentinel nodes than foreign analogues. Its clinical use allows to increase the number of organ-preserving operations in 3-4 times in early breast cancer", – the representative of the medical center told.
© предоставлено пресс-службой ТПУ
She explained that currently TNRMC together with TPU is developing a tumorotropic radiopharmaceutical – 99m Tc-1-thio-D-glucose. Its main advantage – is the ability to visualize the tumor without using positron emission computed tomography technologies, which significantly reduces the cost of the diagnostic procedure.
"The advantage of 99m TC-1-thio-D-glucose is the lack of physiological accumulation in the brain, therefore, the radiopharmaceutical can be used to visualize brain tumors. The first clinical studies suggest that 99m TC-1-thio-D-glucose will occupy a worthy place in the diagnosis and staging of malignant lymphomas and other neoplasms", – the interlocutor specified.
She added that now the industrial partner of the Tomsk Cancer Research Institute under the agreement on mastering the production of new radiopharmaceuticals, concluded in 2018, has begun preparations for the formation of the necessary production infrastructure.